Zydus Lifesciences has introduced Tishtha, the world's first biosimilar of Nivolumab, in India. This represents a significant accomplishment for India in enhancing the accessibility of world-class cancer therapies. Nivolumab is a well-known immuno-oncology medication utilised for the treatment of several cancer types, such as melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck tumours, and Hodgkin lymphoma. The introduction of Tishtha strengthens India's expertise in managing intricate biologic molecules and immunotherapy, establishing the nation as a key contributor to enhancing the accessibility and innovation of cancer treatment at a reasonable price. Zydus additionally mentioned that Tishtha is priced at nearly a quarter of the reference drug's cost, which will enhance the drug's affordability for patients. The 100 mg bottle of the medication is priced at Rs. 28,950 (US$ 322), while the 40 mg vial is priced at Rs. 13,950 (USD 155). The introduction of this biosimilar is anticipated to increase accessibility to immuno-oncology treatment for patients in the Indian market. The introduction of this biosimilar is anticipated to alleviate the financial strain of cancer therapy for patients. The introduction of this biosimilar demonstrates the evolution of India's biologics manufacturing ecosystem, which will enhance India's role in the global biopharmaceutical value chain.